ARTICLE | Clinical News
Iressa gefitinib: Post-marketing study data
August 15, 2005 7:00 AM UTC
Data from a study in 103 patients with various types of NSCLC resistant to Iressa showed that epithelial membrane protein 1 ( EMP1) was expressed in 66% of patients with squamous cell carcinomas and ...